Platform
Multimodal evidence integration.
Molecular target prioritisation.
Asclepius integrates genomic, proteomic, cellular and clinical evidence to support molecular target identification and prioritisation. It connects candidate targets with their supporting biological evidence, generating hypotheses for downstream experimental validation.
target
AntigenPublic structurereasoning
AntigenLiterature- Prior art
- Assay formats
- Known liabilities
- Epitope precedent
Structures · PDBDepositedEpitope mapWhere it landsformats
AntigenscFvVH–VL linkedIgGFull antibodyMultispecificTwo epitopesVHHSingle domainVHHCommittedBound complexMeasuredLeadIn translationdesign
AntigenVHHSingle domainVHHCommittedBound complexMeasuredLeadIn translationlab
AntigenVHHSingle domainVHHCommittedBound complexMeasuredLeadIn translationWet labExpress · measureSelectMeasured · top 4LearnRe-rank · redesigntranslation
AntigenVHHSingle domainVHHCommittedBound complexMeasuredLeadIn translationOne intelligence. Parallel campaigns.
Turn a direction into a candidate.
Give Proteus a target, a mechanism and the constraints. Follow one campaign through reasoning, molecular formats, design, experiments and translation, then see the same workflow across parallel campaigns.
Many campaigns. Shared intelligence.
Multiplexing lets design and evidence return overlap across a portfolio. The aim is greater programme capacity while retaining what each campaign learns. Experiments still take biological time.Evidence → Trial context → Scenarios → Forecast → Observe → Learn.
See beyond the experiment.
Bring programme evidence into clinical context, explore possible outcomes and preserve uncertainty. Freeze the forecast before the result, then let prospective observation inform the next one.